dinaciclib

Ligand id: 7379

Name: dinaciclib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 92.63
Molecular weight 396.23
XLogP 2.01
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
A Phase 3 clinical trial in chronic lymphocytic leukemia (CLL) patients has been completed (see NCT01580228).
Mechanism Of Action and Pharmacodynamic Effects
The CDK4/6 pathway is key to regulating cell growth in many types of human cancer [1,5-6], such as genetic subtypes of non-small cell lung cancer (NSCLC, [2,5,7], melanoma, Mantle cell lymphoma (MCL), and ovarian and breast cancers [2-3]. Inhibiting this pathway prevents cell cycle transition from G1 to S phase, induces cell senescence and in some cases results in apoptosis [2].